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Abstract
Purpose: Diamond–Blackfan anaemia (DBA) is a rare pure congenital red cell aplasia, usually presenting in infancy or early
childhood. The literature suggests a predisposition to haemopoietic malignancy but in addition solid tumours have been
reported, with five cases of osteosarcoma described.
Patient: A sixth case of a 12-year-old girl with DBA who developed an osteosarcoma of the distal femur is presented.
Results: She was treated with methotrexate followed by tumour excision and distal femoral replacement. The patient is
currently alive with multiple pulmonary metastases.
Discussion: We discuss the association between the administration of growth hormone and future development of malignancy
in patients with DBA.
Introduction
Diamond–Blackfan anaemia (DBA) is a rare disorder
characterised by congenital deficiency of red blood
cell precursors resulting in pure red cell aplasia.
Although the risk of malignancy in Diamond–
Blackfan anaemia is unknown, there are a number
of reported cases. A recent review of the literature
1
reveals the majority to be haemopoietic in origin,
namely Hodgkin’s disease, acute lymphoblastic leu-
kaemia (ALL) and acute myeloid leukaemia (AML).
Solid tumours have also been reported, including
hepatocellular carcinoma and breast carcinoma. Five
cases of osteosarcoma have been documented in the
literature and it has been speculated that there is an
association between DBA and osteosarcoma.
1–3 We
present a sixth case of DBA, who is still alive, and
discuss the similarities between our case and those
presented previously.
Case report
A caucasian girl, the second of three children, was
born in 1988 after a normal pregnancy, labour and
delivery. Concern arose after 3–4 months as she was
noted to be lethargic and off her food. By the age of
8 months, her slow growth rate was noted as was
her anaemic appearance. Her haemoglobin level was
subsequently discovered to be 3.5g/dl and bone
marrow examination revealed erythroid hypoplasia,
with all other cell lines being normal. A diagnosis of
Diamond–Blackfan anaemia was made.
She presented with many of the typical dysmorphic
features associated with the syndrome, namely short
stature, short neck, microcephaly, micrognathia,
tow-coloured hair, wide set eyes and snub nose. Both
her thenar eminences were flattened but her thumbs
were of normal appearance and structure. She had
no ocular or renal anomalies.
She was initially treated with only low-dose corti-
costeroids to good effect. It was only from the age of
8 years that she required regular red cell transfusions
with a view to attempting to increase her growth
velocity.
She subsequently developed iron overload and was
treated with subcutaneous desferrioxamine from
the age of 11 years. This was not well tolerated due
to needle phobia and after approximately 11 months
was reverted to steroid treatment, initially at 2mg/kg
reducing to 1mg/kg. At about the same time, she was
commenced on growth hormone to treat her short
stature.
Six weeks after the start of this treatment she devel-
oped intermittent pain in her right thigh. Initially this
Correspondence to: Robert S. Lee, c/o Timothy Briggs, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, Middx,
England. Fax: þ44-20-8909-5709; E-mail: leerobert9@hotmail.com
1357-714X print/1369–1643  2004 Taylor & Francis Ltd
DOI: 10.1080/13577140410001679266was thought to be related to her injections of growth
hormone in her right leg and as a result this was
discontinued. However, examination revealed a firm
selling at the distal end of her right femur. A plain
X-ray showed changes consistent with osteosarcoma.
Magnetic resonance imaging confirmed the presence
of the tumour with no other lesions. A CT chest was
clear and and isotope bone scan showed no evidence
of metastases.
A needle biopsy, performed in April 2001, con-
firmed an osteoblastic osteosarcoma. Prior to surgery
she received a course of chemotherapy, and in July
2001 (4 months after presentation) she underwent
tumour excision (Fig.1)andhad aright distal femoral
replacement.
Histology confirmed osteoblastic osteosarcoma
with a category 1 (99%) response to pre-operative
chemotherapy. The remaining 1% of tumour showed
moderate damage. The circumferential margin was
focally marginal.
Unforunately she subsequently developed multiple
pulmonary metastases requiring thoracoscopic resec-
tion in January and May 2002. Despite two courses
of intravenous methotrexate, she developed more
pulmonary metastases.
In October 2002 she developed sepsis of her distal
femoral replacement and underwent open debride-
ment. She is currently alive with multiple pulmonary
metastases.
Discussion
Diamond–Blackfan anaemia (DBA) is a rare condi-
tion with only approximately 400 cases worldwide.
The majority arise from sporadic mutations, though
in 10% there is a familial link. Our patient exhi-
bited the typical clinical features of DBA. It is well
documented that DBA is associated with myeloid
malignancies, with over 14 cases documented in the
literature.
1 However, the link between DBA and
osteosarcoma is still tenuous with only five previous
cases.
1–3 Our case is the sixth such patient with
osteosarcoma and is the only one who is still alive
and receiving treatment. Of the five previously
reported cases, three died of metastatic pulmonary
disease and two died of sepsis, with a mean survival
of 1.6 years from the time of diagnosis.
The age of presentation of our patient is in line
with the mean age of presentation of the other
reported cases (12 vs. 11 years; range 5–22 years).
Similarly, all those who developed osteosarcoma were
transfusion dependent. One worrying feature is that
our patient is the third out of the six cases to have
developed osteosarcoma following growth hormone
treatment. Lipton et al.
1 initially questioned whether
growth hormone played a role in the development
of osteosarcoma in those with DBA. In a recent study
of 16 children
4 who received growth hormone treat-
ment for intra-uterine growth retardation, one girl
developed an osteosarcoma of her left tibia aged 9
years. A review of the literature also revealed a case of
osteosarcoma in a patient with Albright’s syndrome
following a marked elevation of growth hormone
secondary to a pituitary adenoma.
5 The stimulatory
effects of growth hormone have been well documen-
ted at the cellular level,
6 and it has also been demon-
strated that the proliferation of osteosarcoma cell
lines can be inhibited by antagonists of growth
hormone-releasing hormone (GHRH).
7,8
One important difference between our patient and
the reports in the literature is the length of time bet-
ween the start of growth hormone therapy and the
development of the osteosarcoma. The period in
the two previous reported cases was 18 months and
8 years,
1 respectively, and in Darendeliler et al.’s
4
study the gap was just over 4 years. In comparison,
our case developed an osteosarcoma after only 6
weeks. This short period makes it unlikely that
growth hormone initiated the malignant develop-
ment of the osteosarcoma.
From a histological perspective, it has been
suggested that non-common subtypes of osteosar-
coma may be predictive of patients with rare cancer
syndromes.
9 However, our patient had a common
subtype. Unfortunately the fine histological detail of
the previous five cases is not reported.
In conclusion, we present a sixth case of
osteosarcoma in transfusion-dependent Diamond–
Blackfan anaemia, who is currently alive with
Fig. 1. Digitalised X-ray image of a 4-mm slice through the
proximal tibia showing the osteosarcoma lesion.
48 R. S. Lee et al.pulmonary metastases. This adds further evidence
to the association between theses two relatively rare
conditions.
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